Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

52 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial.
Samalin E, Bouché O, Thézenas S, Francois E, Adenis A, Bennouna J, Taieb J, Desseigne F, Seitz JF, Conroy T, Galais MP, Assenat E, Crapez E, Poujol S, Bibeau F, Boissière F, Laurent-Puig P, Ychou M, Mazard T. Samalin E, et al. Among authors: boissiere f. Br J Cancer. 2014 Mar 4;110(5):1148-54. doi: 10.1038/bjc.2013.813. Epub 2014 Jan 9. Br J Cancer. 2014. PMID: 24407191 Free PMC article. Clinical Trial.
TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy.
Oden-Gangloff A, Di Fiore F, Bibeau F, Lamy A, Bougeard G, Charbonnier F, Blanchard F, Tougeron D, Ychou M, Boissière F, Le Pessot F, Sabourin JC, Tuech JJ, Michel P, Frebourg T. Oden-Gangloff A, et al. Among authors: boissiere f. Br J Cancer. 2009 Apr 21;100(8):1330-5. doi: 10.1038/sj.bjc.6605008. Br J Cancer. 2009. PMID: 19367287 Free PMC article.
Antibody targeting of claudin-1 as a potential colorectal cancer therapy.
Cherradi S, Ayrolles-Torro A, Vezzo-Vié N, Gueguinou N, Denis V, Combes E, Boissière F, Busson M, Canterel-Thouennon L, Mollevi C, Pugnière M, Bibeau F, Ychou M, Martineau P, Gongora C, Del Rio M. Cherradi S, et al. Among authors: boissiere f. J Exp Clin Cancer Res. 2017 Jun 28;36(1):89. doi: 10.1186/s13046-017-0558-5. J Exp Clin Cancer Res. 2017. PMID: 28659146 Free PMC article.
Prognostic value of androgen receptor and FOXA1 co-expression in non-metastatic triple negative breast cancer and correlation with other biomarkers.
Guiu S, Mollevi C, Charon-Barra C, Boissière F, Crapez E, Chartron E, Lamy PJ, Gutowski M, Bourgier C, Romieu G, Simony-Lafontaine J, Jacot W. Guiu S, et al. Among authors: boissiere f. Br J Cancer. 2018 Jul;119(1):76-79. doi: 10.1038/s41416-018-0142-6. Epub 2018 Jun 8. Br J Cancer. 2018. PMID: 29880907 Free PMC article.
Targeting the p38 MAPK pathway inhibits irinotecan resistance in colon adenocarcinoma.
Paillas S, Boissière F, Bibeau F, Denouel A, Mollevi C, Causse A, Denis V, Vezzio-Vié N, Marzi L, Cortijo C, Ait-Arsa I, Askari N, Pourquier P, Martineau P, Del Rio M, Gongora C. Paillas S, et al. Among authors: boissiere f. Cancer Res. 2011 Feb 1;71(3):1041-9. doi: 10.1158/0008-5472.CAN-10-2726. Epub 2010 Dec 15. Cancer Res. 2011. PMID: 21159664 Free PMC article.
Proteomic analysis of RCL2 paraffin-embedded tissues.
Bellet V, Boissière F, Bibeau F, Desmetz C, Berthe ML, Rochaix P, Maudelonde T, Mangè A, Solassol J. Bellet V, et al. Among authors: boissiere f. J Cell Mol Med. 2008 Oct;12(5B):2027-36. doi: 10.1111/j.1582-4934.2008.00186.x. J Cell Mol Med. 2008. PMID: 19012729 Free PMC article.
Oestrogen receptor negative breast cancers exhibit high cytokine content.
Chavey C, Bibeau F, Gourgou-Bourgade S, Burlinchon S, Boissière F, Laune D, Roques S, Lazennec G. Chavey C, et al. Among authors: boissiere f. Breast Cancer Res. 2007;9(1):R15. doi: 10.1186/bcr1648. Breast Cancer Res. 2007. PMID: 17261184 Free PMC article.
52 results